Specialty pharmaceutical company Delcath Systems Inc (DCTH) Friday revealed that the European Institute of Oncology, a premier cancer treatment and research center in Milan has performed the first treatment using the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System.
The company stated that a patient was treated for inoperable liver-dominant metastases from ocular melanoma, a case that represents the first use of the second generation hemofiltration cartridge in a clinical setting.
"We are pleased to finally be able to provide the second generation CHEMOSAT system to our early launch centers in Europe," said Eamonn P. Hobbs, President and CEO of Delcath Systems. "Now that we are beginning to treat patients with the new system, we are confident that efficiency data we've seen in our in vivo studies will be validated in actual clinical use. We are also pleased that the team at the IEO is the first to begin exploring the benefits of the new system, and look forward to working with them and other early launch centers to establish the benefits of this system for patients with cancers in the liver."
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org